文献速递神经MR

一项减少多发性硬化患者不必要的钆基对比剂使用的倡议

An Initiative to Reduce Unnecessary Gadolinium-Based Contrast in Multiple Sclerosis Patients.
PubMed 文献 · J Am Coll Radiol · 2019-05-16

该前瞻性质量改进项目利用院内计算机辅助检测(CAD)软件和3-D实验室放射科技师,对多发性硬化(MS)患者随访MRI的非增强T2 FLAIR图像进行实时初步评估,仅对有新疾病活动证据者注射钆基对比剂。2个月试验期内153例患者按新方案成像,技师识别新发或增大病灶的准确率为95%、阴性预测值为97%,87%的患者避免了对比剂使用。

要点

  • 技师借助CAD软件实时评估非增强T2 FLAIR图像,识别新发或增大病灶的准确率为95%、阴性预测值为97%。
  • 该方案使87%的随访MRI患者避免使用钆基对比剂及额外成像序列。
  • 实施前经神经内科、神经放射科和MR技师多学科会议及问卷调查评估意见与障碍。

核心结论

  • 多学科协作实施的质量改进项目通过实时靶向筛选可从静脉对比剂获益的患者,在MS随访MRI中减少了钆基对比剂使用,并改善了安全性和成本。

研究设计与样本

  • 前瞻性质量改进项目,2个月试验期内153例MS患者按新方案行随访MRI,以非增强T2 FLAIR的CAD处理图像作为是否注射对比剂的决策依据,以最终神经放射科医师判读为参考标准。

关键影像表现/征象

  • 技师使用CAD软件在FLAIR图像上识别新发或增大病灶,相对于最终神经放射科医师判读的准确率为95%、阴性预测值为97%。
  • 基于上述评估,87%的患者避免了对比剂使用及额外成像序列。

诊断标准与关键数值

  • 静脉对比剂仅保留给非增强图像上有新疾病活动证据的患者。
  • 技师使用CAD软件识别新发或增大病灶的准确率为95%,阴性预测值为97%,参考标准为最终神经放射科医师判读。

临床应用与阅片要点

  • 实施前召开神经内科、神经放射科和MR技师多学科会议并发放问卷调查,以客观评估意见和临床实施障碍。
  • 由3-D实验室放射科技师在检查过程中对CAD处理的T2 FLAIR非增强图像进行实时初步评估,作为是否注射对比剂的依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Patients with multiple sclerosis (MS) routinely undergo serial contrast-enhanced MRIs. Given concerns regarding tissue deposition of gadolinium-based contrast agents (GBCAs) and evidence that enhancement of lesions is only seen in patients with new disease activity on noncontrast imaging, we set out to implement a prospective quality improvement project whereby intravenous contrast would be reserved only for patients with evidence of new disease activity on noncontrast images.

METHODS: To prospectively implement such a protocol, we leveraged our in-house computer-assisted detection (CAD) software and 3-D laboratory radiology technologists to perform real-time preliminary assessments of the CAD-processed T2 fluid attenuated inversion recovery (FLAIR) noncontrast images as a basis for deciding whether to inject contrast. Before implementation, we held multidisciplinary meetings with neurology, neuroradiology, and MR technologists and distributed surveys to objectively assess opinions and obstacles to clinical implementation. We evaluated reduction in GBCA utilization and technologist performance relative to final neuroradiologist interpretations.

RESULTS: During a 2-month trial period, 153 patients were imaged under the new protocol. Technologists using the CAD software were able to identify patients with new or enlarging lesions on FLAIR images with 95% accuracy and 97% negative predictive value relative to final neuroradiologist interpretations, which allowed us to avoid the use of contrast and additional imaging sequences in 87% of patients.

DISCUSSION: A multidisciplinary effort to implement a quality improvement project to limit contrast in MS patients receiving follow-up MRIs allowed for improved safety and cost by targeting patients that would benefit from the use of intravenous contrast in real-time.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Rudie JD, Mattay RR, Schindler M, et al. An Initiative to Reduce Unnecessary Gadolinium-Based Contrast in Multiple Sclerosis Patients. J Am Coll Radiol. 2019. PMID: 31092348. doi:10.1016/j.jacr.2019.04.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。